QT Imaging Signs Distribution Agreement With Freedom Ventures for Breast Scanner

QT Imaging’s U.S. Food and Drug-Administration (FDA)-cleared 3D breast imaging technology will soon be available on two other continents.

Through an agreement with Freedom Ventures B.V., the company’s QT Scan will become an option for patients in Europe, the Middle East, and North Africa. 

“As a small company, working with an established distribution network provides us global market reach while being able to maintain the level of quality in marketing, sales, technical service, and most importantly patient care, that we have established in the United States. Freedom Ventures has the experience to be that partner in this important region,” says Meg Donigan, chief operating officer at QT Imaging. Freedom Ventures will also assist QT Imaging in securing a CE Mark and manage the registration process in its markets.

Freedom Ventures, a Dutch company which will conduct business as QT Scan BV, is well-established in the field of medical devices, with an extensive network of distributers, and a Center of Excellence for technical, marketing, and clinical training.

The European medical imaging market, currently valued at $38 billion, is expected to grow almost 10 percent annually over the next decade, with advancements in medical imaging technology driving that increased demand. QT’s medical imaging technology generates 3D images with remarkable accuracy and precision, and the volumetric images are produced without the need of contrast injections or radiation. The QTscan is an FDA-cleared breast imaging tool, and the company will seek CE marking to provide confidence to the healthcare community that the device meets EU safety, health, and environmental protection requirements before market launch.
 
Rutger Brest van Kempen, CEO of Freedom Ventures, said “We’re very excited about the opportunity the radiation-free QTscan has to fill a unique need in the European breast imaging market where women are being screened later and less frequently due to concerns about radiation. In the Middle East and North Africa, this new technology will also be embraced for its ease of adoption as it requires no costly facilities or special licensing for operators. Hisham Hasaan, Freedom Ventures Vice-President for the Middle East and Africa says, “With QTscan we will have a huge opportunity to screen woman, who now have to travel far to hospitals where radiology equipment is available whereas our technologies can be installed virtually anywhere. We will focus on creating regional QTscan centers to bring this unique technology to the masses.”